Launch One Acquisition Corp. Unit (LPAAU)

🚫 Launch One Acquisition Corp. Unit does not pay dividends

Company News

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Benzinga • Globe Newswire • October 15, 2025

Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201, a novel cell therapy targeting Myelodysplastic Syndrome (MDS), and announced a planned business combination with Launch One Acquisition Corp.

LPAALPAAW